You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 159 No. 10, May 24, 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Weight Watching in Heparin

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I read with interest the excellent article by Harrison et al1 on low-molecular-weight heparin (LMWH) for outpatient treatment of patients with deep venous thrombosis (DVT). In clinical studies on the prevention and treatment of DVT, LMWH proved at least equal and in some cases superior to unfractionated heparin in efficacy and safety.2-3

This success of LMWH in the management of DVT has prompted several investigators to study the use of LMWH in acute coronary syndromes. Three recently completed trials—the FRagmin during InStability in Coronary artery disease study (FRISC),4 the Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events study (ESSENCE),5 and the FRagmin In unstable Coronary artery disease study (FRIC)6—concluded that treatment of patients with unstable angina with LMWH is at least as effective as and potentially more effective than with unfractionated heparin.

In addition to the favorable results comparing LMWH with unfractionated heparin based on the STEP . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Assessment of Outpatient Treatment of Deep-Vein Thrombosis With Low-Molecular-Weight Heparin
Linda Harrison, Joanne McGinnis, Mark Crowther, Jeffrey Ginsberg, and Jack Hirsh
Arch Intern Med. 1998;158(18):2001-2003.
ABSTRACT | FULL TEXT  

Treatment of Deep Venous Thrombosis With Low-Molecular-Weight Heparins: A Meta-analysis
Anthonie W. A. Lensing, Martin H. Prins, Bruce L. Davidson, and Jack Hirsh
Arch Intern Med. 1995;155(6):601-607.
ABSTRACT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low-Molecular-Weight Heparin for Unstable Angina
Cheng
Chest 1999;116:1833-1833.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.